Loading
SYK (Tyrosine-protein kinase SYK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Skin cancer, Lung cancer and 4 more.
Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signalling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Paclitaxel. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes clinical 0.50, literature 0.99, genetic association 0.38, somatic mutation 0.98, animal model 0.51). In OnCo, 1 product record names it (Fostamatinib).
In plain words · SYK (Tyrosine-protein kinase SYK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Skin cancer, Lung cancer and 4 more.
SYK (Tyrosine-protein kinase SYK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Skin cancer, Lung cancer and 4 more.
Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR).
No product in this corpus aims at SYK yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-associated overexpression: HPA finds the RNA tissue enhanced in normal lymphoid tissue, parathyroid gland, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA SYK: RNA tissue enhanced (lymphoid tissue 69 nTPM, parathyroid gland 82 nTPM); high antibody staining in 13 normal tissues; highest cancer staining lymphoma (8 of 11 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Skin cancer (all types), Lung cancer (all types), Breast cancer (all types), Colorectal cancer, Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas SYK tissue; Human Protein Atlas SYK pathology; Open Targets ENSG00000165025 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Yagi et al, Biochem. Biophys. Res. Commun, 1994, "Cloning of the cDNA for the deleted syk kinase homologous to ZAP-70 from human basophilic leukemia cell line (KU812)". Source.
Sources: HGNC HGNC:11491 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P43405 (protein name, function text, keywords and locations (REST API)); CIViC gene SYK (1 evidence items, 0 assertions, 1 variants; diseases: Ovarian Cancer (GraphQL API, CC0)); Open Targets ENSG00000165025 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: colorectal cancer 0.54, melanoma 0.56, skin cancer 0.58, breast cancer 0.54, lung cancer 0.55, leukaemia 0.50 (GraphQL API, CC0))
Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signalling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Location: Cell membrane; Cytoplasm, cytosol (UniProt). Locus 9q22.2 (HGNC).
RNA: tissue enhanced (lymphoid tissue 69 nTPM, parathyroid gland 82 nTPM), detected in many normal tissues.
Medium: Caudate, Cerebral cortex, Cervix, Colon, Endometrium, Epididymis, Esophagus, Gallbladder.
Medium only: breast cancer, carcinoid, head and neck cancer, pancreatic cancer.
HPA SYK tissue · HPA SYK pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SYK" OR ABSTRACT:"SYK" OR TITLE:"spleen associated tyrosine kinase" OR ABSTRACT:"spleen associated tyrosine kinase" OR TITLE:"Tyrosine-protein kinase SYK" OR ABSTRACT:"Tyrosine-protein kinase SYK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SYK, not a curated reading list.
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, Leukaemia (all types), Skin cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), CIViC, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), CIViC, Breast cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), Ovarian cancer, Breast cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), Ovarian cancer, Lung cancer (all types).
Shares Leukaemia (all types), CIViC, Ovarian cancer, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), CIViC, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), Lung cancer (all types), Breast cancer (all types).